Research programme: vasopressin 2 antagonists - Predix
Latest Information Update: 21 Aug 2007
At a glance
- Originator Predix Pharmaceuticals
- Class
- Mechanism of Action Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Liver cirrhosis; Nephrosis
Most Recent Events
- 27 Mar 2006 No development reported - Preclinical for Cirrhosis in USA (unspecified route)
- 27 Mar 2006 No development reported - Preclinical for Congestive heart failure in USA (unspecified route)
- 27 Mar 2006 No development reported - Preclinical for Nephrosis in USA (unspecified route)